Woolson Daniel sold $982K of ICUI

Woolson Daniel (VP, GM-Infusion Capital) sold 5,417 shares of ICU MEDICAL INC/DE (ICUI) at $181.33 ($0.98M total) on 2026-08-13.

Original reporting
SEC EDGAR · Woolson Daniel
Published Aug 13, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ICUI
Neutral
medium confidence
Mentioned
$ICUI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICUINeutralLow
01

Why it matters

Traders may monitor insider activity as a sentiment input, but this filing alone does not change earnings power, valuation, or near-term fundamentals.

02

Market read

A new Form 4 sale provides incremental sentiment information for ICUI, but it is unlikely to be a standalone catalyst.

03

What to watch

The transaction is an open-market sale and the article provides no context on total compensation, prior holdings, or whether other insiders sold/bought around the same time.

Relevance 5/10Novelty 5/10Timing: filed 2026-08-13 after-hours/late session

Background

The article is an SEC Form 4 insider transaction disclosure for ICU Medical, Inc. (ICUI).

Company-level read

Ticker impact

$ICUINeutralMedium confidence
Context

ICU Medical disclosed an insider open-market sale by VP, GM-Infusion Capital Woolson Daniel of 5,417 shares at $181.33 on 2026-08-13.

Expected impact

Likely limited, short-lived sentiment impact; follow-through depends on broader flow and any concurrent company news.

Evidence & confidence

Form 4 insider sales are common and the filing states no pre-arranged 10b5-1 plan, but it still does not provide new operating or guidance information.

Market effects

Minimal sector read-through; this is an issuer-specific insider sale without stated operational drivers.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or personal liquidity needs and may not signal reduced business confidence.

Key entities

  • ICU Medical, Inc.

    Company subject of the Form 4 insider transaction disclosure.

  • Woolson Daniel

    VP, GM-Infusion Capital who sold 5,417 shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ICUIHighAI 8/10

ICU Medical (ICUI) Q3 2026 Earnings Call Transcript

ICU Medical (ICUI) reported Q3 2026 adjusted EPS of $2.44, up 20% YoY, with adjusted EBITDA at $114M. Revenue growth was driven by consumables (+5%) and IV systems (+11%), while Vital Care declined (-10%). The company expects full-year EBITDA and EPS to be at the higher end of previous guidance.

$ICUIMedAI 8/10

ICU Medical Inc (ICUI) Q3 2026 Earnings Call Highlights: Record Sales, 20% EPS Growth

ICU Medical Inc reported Q3 2026 earnings with 11% growth in Infusion Systems, driven by competitive wins and customer utilization. The company aims for a 43% gross margin by 2027, with potential for earlier achievement. FDA requested additional testing for MedFusion 5,000 syringe pump and ambulatory pump submissions. Management discussed macroeconomic challenges, currency impacts, and strategic initiatives like the Otsuka joint venture.

$ICUIHigh

ICU Medical Q3 Earnings Call Highlights

ICU Medical (ICUI) reported Q3 earnings, noting delayed Infusion Systems volume and revised growth expectations. Vital Care revenue declined 12% due to logistics issues, with full-year decline expected to be larger than anticipated. Adjusted gross margin expanded to 42%, with debt reduction continuing. The company maintained 2026 guidance but lowered capital spending forecasts.

$ICUIHighAI 8/10

ICU Medical: Q3 Earnings Snapshot

ICU Medical Inc. (ICUI) reported Q3 net income of $26.8M, or $1.07 per share, beating estimates. Adjusted EPS was $2.44, and revenue was $560.4M, also exceeding forecasts. The company expects full-year EPS of $8.60-$9.00.